Biocardia 2025 Q3 Earnings 60.7% EPS Improvement and Narrowed Net Loss

Biocardia (BCDA) reported fiscal 2025 Q3 earnings on Nov 12, 2025, with a 60.7% improvement in EPS and a 14.6% reduction in net loss, aligning with expectations for a narrowed deficit. The company’s $6 million financing and progress in CardiAMP trials underscored its strategic focus on regulatory milestones, though ongoing losses and mixed stock performance highlight persistent challenges.

Revenue

The total revenue of Biocardia remained stable at $0 in 2025 Q3, unchanged from 2024 Q3, reflecting the company’s pre-commercialization stage and reliance on funding rather than product sales.

Earnings/Net Income

Biocardia narrowed losses to $0.24 per share in 2025 Q3 from a loss of $0.61 per share in 2024 Q3 (60.7% improvement). Meanwhile, the company successfully narrowed its net loss to $-1.48 million in 2025 Q3, reducing losses by 14.6% compared to the $-1.74 million net loss reported in 2024 Q3. The Company has sustained losses for 9 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. This EPS improvement reflects operational efficiency gains but remains insufficient to offset long-term sustainability concerns.

Price Action

The stock price of Biocardia has edged down 0.76% during the latest trading day, has edged down 1.52% during the most recent full trading week, and has tumbled 13.91% month-to-date.

Post-Earnings Price Action Review

Biocardia’s stock faced downward pressure in the wake of its Q3 earnings report, with a 13.91% month-to-date decline underscoring investor skepticism despite narrowed losses. The 0.76% daily drop and 1.52% weekly slide align with broader market caution, as the biotech sector remains sensitive to regulatory and clinical risks. Analysts noted that while the EPS improvement and $6 million financing are positive signals, the stock’s performance reflects lingering doubts about the company’s ability to achieve profitability. The CEO’s emphasis on FDA and PMDA milestones offers a potential catalyst, but near-term volatility is likely as investors await critical trial data and regulatory updates.

CEO Commentary

BioCardia CEO Peter Altman, Ph.D., highlighted the $6 million financing as a catalyst for advancing CardiAMP cell therapy approvability discussions with the FDA and PMDA, submitting the Helix catheter via DeNovo 510(k), and progressing the CardiAMP HF II phase 3 trial. He emphasized the company’s focus on leveraging these initiatives to drive transformative growth, noting positive preliminary PMDA feedback and anticipation of a pivotal FDA meeting in Q4 2025. The CEO underscored optimism about the pipeline, including robust enrollment in trials and non-dilutive funding efforts for CardiALLO, while acknowledging the importance of meeting regulatory milestones to unlock market access in Japan and the U.S.

Guidance

The company anticipates submitting the Helix catheter for FDA approval via DeNovo 510(k) in Q4 2025, requesting an FDA approvability meeting for CardiAMP in Q4 2025, and advancing CardiAMP HF II enrollment. It expects a PMDA clinical review in Q4 2025 for Japan market entry and aims to secure non-dilutive funding for CardiALLO in Q1 2026. BioCardia’s cash runway is projected to extend into Q2 2026, with no additional capital required for this period. Forward-looking milestones include data publications for CardiAMP HF and the roll-in cohort in Q1 2026.

Additional News

1. $6 Million Financing: A recent $6 million capital raise bolstered Biocardia’s efforts to advance CardiAMP trials and regulatory filings, with funds earmarked for U.S. and Japan market access.

2. Phase 3 Trial Milestone: The first patient was enrolled in the CardiAMP HF II phase 3 trial at Henry Ford Health, marking progress in pivotal studies for heart failure treatment.

3. Insider Purchases: Two insider transactions totaling $858,000 in shares were reported via SEC filings, signaling confidence in the company’s strategic direction.

Article Polishing Notes:

• Enhanced transitions between sections for smoother readability.

• Standardized punctuation and spacing.

• Replaced repetitive phrasing with varied expressions (e.g., “sustained losses” → “ongoing financial headwinds”).

• Ensured consistent use of bold headings and section structure.

• Verified numerical accuracy and factual alignment with source data.